LB has served as a consultant for AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk and Sanofi, has participated in speaker bureaus for AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Novo Nordisk and Sanofi, and has received research support from AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk and Sanofi
Sun M, Sun X, Wang F, Liu L
They are self-injected, often into the thigh, upper arm, or abdomen
Source: GLP-1.Reviews editorial walkthrough on April 29, 2026
Although dual and triagonist medications have so far exhibited side effects comparable to those of GLP- 1 receptor monoagonists in human trials, these preclinical findings imply that GIP receptor agonism may be the secret to obtaining the weight loss advantages of incretin agonism with less severe side effects